In our study, only one patient with a B2M-mutant tumor and several metastases not restricted to peritoneal or lymphatic sites was treated with a combination of anti-CTLA-4 and anti-PD-l antibodies (ipilimumab and nivolumab) and demonstrated SD as best response. The gene discussed is B2M; the disease is neoplasm.